HomeCompareREV vs MRK

REV vs MRK: Dividend Comparison 2026

REV yields 4.28% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $31.3K in total portfolio value
10 years
REV
REV
● Live price
4.28%
Share price
$3.90
Annual div
$0.17
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.5K
Annual income
$563.55
Full REV calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — REV vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodREVMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, REV + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
REV pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

REV
Annual income on $10K today (after 15% tax)
$363.98/yr
After 10yr DRIP, annual income (after tax)
$479.02/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, MRK beats the other by $8,117.70/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of REV + MRK for your $10,000?

REV: 50%MRK: 50%
100% MRK50/50100% REV
Portfolio after 10yr
$42.1K
Annual income
$5,338.67/yr
Blended yield
12.69%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

REV
Analyst Ratings
2
Hold
Consensus: Hold
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

REV buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricREVMRK
Forward yield4.28%2.81%
Annual dividend / share$0.17$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$26.5K$57.7K
Annual income after 10y$563.55$10,113.78
Total dividends collected$5.0K$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: REV vs MRK ($10,000, DRIP)

YearREV PortfolioREV Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$11,128$428.22$11,213$373.04$85.00MRK
2$12,353$445.35$12,667$512.06$314.00MRK
3$13,679$462.01$14,439$708.14$760.00MRK
4$15,115$478.16$16,640$988.16$1.5KMRK
5$16,667$493.78$19,432$1,394.07$2.8KMRK
6$18,342$508.86$23,057$1,992.90$4.7KMRK
7$20,150$523.38$27,889$2,894.79$7.7KMRK
8$22,097$537.33$34,518$4,286.29$12.4KMRK
9$24,195$550.72$43,912$6,494.35$19.7KMRK
10$26,452$563.55$57,714$10,113.78$31.3KMRK

REV vs MRK: Complete Analysis 2026

REVStock

Revlon, Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells beauty and personal care products worldwide. The company's Relvon segment offers color cosmetics and beauty tools under the Revlon brand; and hair color under the Revlon ColorSilk and Revlon Professional brands. Its Elizabeth Arden segment markets, distributes, and sells skin care products under the Elizabeth Arden Ceramide, Prevage, Eight Hour, SUPERSTART, Visible Difference, and Skin Illuminating brands; and fragrances under the Elizabeth Arden White Tea, Elizabeth Arden Red Door, Elizabeth Arden 5th Avenue, and Elizabeth Arden Green Tea brands. The company's Portfolio segment offers color cosmetics under the Almay and SinfulColors brands; men's grooming products under the American Crew brand; nail polishes, gel nail color, and nail enhancements under the CND brand; nail care products under the Cutex brand; anti-perspirant deodorants under the Mitchum brand; hair care products under the Creme of Nature; and hair color line under the Llongueras brand. Its Fragrances segment develops, markets, and distributes owned and licensed fragrances, as well as distributes prestige fragrance brands owned by third parties. This segment offers its products under the Juicy Couture, John Varvatos, AllSaints, Britney Spears, Elizabeth Taylor, Christina Aguilera, Jennifer Aniston, Mariah Carey, Curve, Giorgio Beverly Hills, Ed Hardy, Charlie, Lucky Brand, Alfred Sung, Halston, Geoffrey Beene, and White Diamonds brands. It sells its products through sales force, sales representatives, independent distributors, mass and prestige retail, e-commerce sites, department stores, and specialty cosmetics stores, as well as licenses its Revlon and other trademarks to the manufacturers of complementary beauty-related products and accessories. Revlon, Inc. was founded in 1932 and is based in New York, New York. On June 15, 2022, Revlon, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

Full REV Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this REV vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

REV vs SCHDREV vs JEPIREV vs OREV vs KOREV vs MAINREV vs JNJREV vs ABBVREV vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.